Urinary Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for Renal Injury in Liver Transplant Recipients Using Calcineurin Inhibitors

2018 ◽  
Vol 50 (10) ◽  
pp. 3667-3672
Author(s):  
K.C. Yoon ◽  
K.-W. Lee ◽  
S.C. Oh ◽  
H. Kim ◽  
H.-S. Kim ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Renal Injury ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase ◽  
Liver Transplant Recipients

scholarly journals Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus

2019 ◽  
Vol 20 (12) ◽  
pp. 3103 ◽  
Author(s):  
Mio Fukuda ◽  
Kimitaka Suetsugu ◽  
Soichiro Tajima ◽  
Yurie Katsube ◽  
Hiroyuki Watanabe ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Acute Kidney Injury ◽  
Mycophenolate Mofetil ◽  
Liver Transplant ◽  
Kidney Injury ◽  
Transplant Recipients ◽  
Fatty Acid Binding ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase ◽  
Liver Transplant Recipients

Tacrolimus is widely used as an immunosuppressant in liver transplantation, and tacrolimus-induced acute kidney injury (AKI) is a serious complication. The urinary neutrophil gelatinase-associated lipocalin (NGAL) level has been linked to tacrolimus-induced AKI in patients starting tacrolimus treatment the morning after liver transplantation. Here we tested this association using a different immunosuppression protocol: Mycophenolate mofetil administration beginning on Postoperative Day 1 and tacrolimus administration beginning on Postoperative Day 2 or 3. Urine samples were collected from 26 living donor liver transplant recipients before (Postoperative Day 1) and after (Postoperative Day 7 or 14) tacrolimus administration. NGAL levels were measured via enzyme-linked immunosorbent assays, as were those of three additional urinary biomarkers for kidney diseases: Monocyte chemotactic protein-1 (MCP-1), liver-type fatty acid-binding protein (L-FABP), and human epididymis secretory protein 4 (HE4). HE4 levels after tacrolimus administration were significantly higher in patients who developed AKI (n = 6) than in those who did not (n = 20), whereas NGAL, MCP-1, and L-FABP levels did not differ significantly before or after tacrolimus administration. These findings indicate that NGAL may not be a universal biomarker of AKI in tacrolimus-treated liver transplant recipients. To reduce the likelihood of tacrolimus-induced AKI, our immunosuppression protocol is recommended.

Impaired erythropoietin production in liver transplant recipients: The role of calcineurin inhibitors

2006 ◽  
Vol 12 (11) ◽  
pp. 1649-1654 ◽  
Author(s):  
Valérie Bardet ◽  
Alcindo Pissaia Junior ◽  
Joël Coste ◽  
Carinne Lecoq-Lafon ◽  
Sandrine Chouzenoux ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Erythropoietin Production ◽  
Liver Transplant Recipients

ACE Gene D/D Genotype as a Risk Factor for Chronic Nephrotoxicity from Calcineurin Inhibitors in Liver Transplant Recipients

2006 ◽  
Vol 81 (3) ◽  
pp. 463-468 ◽  
Author(s):  
Lorenzo Gallon ◽  
Enver Akalin ◽  
Patrick Lynch ◽  
Laura Rothberg ◽  
Michele Parker ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Transplant ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Ace Gene ◽  
Liver Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document